文献速递前列腺癌

解读雄激素剥夺治疗期间睾酮与同步PSA值的关系

Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
PubMed 文献 · J Urol · 2021-06-29

该研究基于PR.7试验持续ADT组中生化复发前列腺癌患者,评估ADT期间睾酮水平与同步PSA对临床结局的预后价值。结果显示同步PSA的预后价值超过睾酮,睾酮突破次数与CRPC时间、CSS或OS无关,但去势水平睾酮需结合ADT起始时间和同步PSA综合解读。

要点

  • ADT期间同步PSA的预后价值超过睾酮水平。
  • 睾酮突破次数与CRPC、CSS或OS风险无关。
  • 去势睾酮值需结合ADT起始时间和同步PSA解读。

核心结论

  • 在本大型长期随访试验中,睾酮突破与CRPC时间、CSS或OS无关。
  • ADT期间的去势睾酮值提供预后信息,但必须结合ADT起始时间和同步PSA值来考虑。

研究设计与样本

  • 纳入PR.7试验中用于放疗后生化复发前列腺癌的间歇ADT方案里的持续ADT组患者。
  • 采用Kaplan-Meier和Cox回归分析评估睾酮水平与同步PSA的预后重要性及睾酮突破次数与结局的关系。

主要发现

  • 睾酮对结局的预后重要性被同步PSA值的预后价值所掩盖。
  • 治疗第一年内出现睾酮值>0.7 nmol/l与随后>1.7 nmol/l的升高相关。
  • 每位患者的睾酮突破次数与CRPC风险、CSS或OS无关。
  • 时间依赖调整分析显示PSA值具有预后价值,但相对累积睾酮暴露与结局无关联。

关键数值与推荐

  • 睾酮突破定义为>1.7 nmol/l。
  • 第一年内睾酮值>0.7 nmol/l与随后>1.7 nmol/l升高相关。

临床怎么用

  • ADT期间监测睾酮时,应同时关注同步PSA值以评估预后。
  • 解读去势睾酮值需考虑ADT起始时间和同步PSA水平。
  • 睾酮突破次数不宜单独用于预测CRPC、CSS或OS风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Measurement of testosterone levels during androgen deprivation therapy (ADT) is broadly recommended, but how therapy should be altered in response to testosterone values during ADT remains controversial. Our objective was therefore to evaluate the relation between testosterone and concomitant prostate specific antigen (PSA) levels during ADT on clinical outcomes. MATERIALS AND METHODS: Patients from the continuous androgen deprivation arm of the PR.7 trial of intermittent ADT for biochemically recurrent prostate cancer following radiotherapy were included. Statistical analyses evaluated the prognostic importance of testosterone levels during ADT relative to concomitant PSA levels. We similarly evaluated whether the number of testosterone breakthroughs >1.7 nmol/l predicted the time to castrate-resistant prostate cancer (CRPC), cancer specific survival (CSS) or overall survival (OS) with Kaplan-Meier and Cox regression analyses. RESULTS: Overall, the prognostic importance of testosterone on outcomes was eclipsed by the prognostic value of concomitant PSA values. The occurrence of testosterone values >0.7 nmol/l in the first year of therapy was associated with subsequent rises >1.7 nmol/l, but the number of testosterone breakthroughs per patient had no relationship to the risk of CRPC, CSS or OS. A time-dependent adjusted analysis indicated as expected that PSA values were prognostic, but there was no association of relative cumulative testosterone exposure with outcomes. CONCLUSIONS: In this large-scale trial with long followup, breakthrough testosterone was unrelated to time to CRPC, CSS or OS. Castrate testosterone values during ADT for recurrent prostate cancer provides prognostic information that must be considered alongside the time since ADT initiation and concomitant PSA values.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Tremblay S, Summers-Trasiewicz L, Pouliot F, et al. Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer. J Urol. 2021. PMID: 34184929. doi:10.1097/JU.0000000000001946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。